Yubo International Biotech Limited (YBGJ)
OTCMKTS
· Delayed Price · Currency is USD
0.0115
+0.0011 (10.58%)
Mar 6, 2026, 4:00 PM EST
YBGJ Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | -0 | 0 | 0.6 | 0.1 | 1.24 | 1.35 | Upgrade
|
| Revenue Growth (YoY) | - | -99.43% | 479.84% | -91.62% | -8.09% | - | Upgrade
|
| Cost of Revenue | -0 | 0.21 | 0.19 | 0.05 | 0.42 | 0.11 | Upgrade
|
| Gross Profit | 0 | -0.21 | 0.42 | 0.05 | 0.82 | 1.24 | Upgrade
|
| Selling, General & Admin | 1.01 | 1.25 | 1.11 | 1.05 | 1.49 | 1.2 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Other Operating Expenses | 0.07 | 0.34 | 0.32 | 0.23 | 0.8 | 0.74 | Upgrade
|
| Operating Expenses | 1.26 | 1.77 | 1.61 | 1.26 | 2.36 | 1.95 | Upgrade
|
| Operating Income | -1.26 | -1.98 | -1.19 | -1.21 | -1.54 | -0.71 | Upgrade
|
| Interest Expense | -0 | - | -0 | - | - | -0 | Upgrade
|
| Interest & Investment Income | 0 | 0 | - | 0 | 0 | - | Upgrade
|
| Pretax Income | -1.26 | -1.98 | -1.2 | -1.2 | -1.54 | -0.71 | Upgrade
|
| Earnings From Continuing Operations | -1.26 | -1.98 | -1.2 | -1.2 | -1.54 | -0.71 | Upgrade
|
| Minority Interest in Earnings | 0.15 | 0.21 | - | - | - | - | Upgrade
|
| Net Income | -1.11 | -1.78 | -1.2 | -1.2 | -1.54 | -0.71 | Upgrade
|
| Net Income to Common | -1.11 | -1.78 | -1.2 | -1.2 | -1.54 | -0.71 | Upgrade
|
| Shares Outstanding (Basic) | 127 | 120 | 12 | 119 | 118 | 116 | Upgrade
|
| Shares Outstanding (Diluted) | 127 | 120 | 12 | 119 | 118 | 116 | Upgrade
|
| Shares Change (YoY) | 959.17% | 900.00% | -89.91% | 0.50% | 1.94% | 1058.84% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.10 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.10 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Free Cash Flow | -1.65 | -1.34 | -0.74 | -0.6 | -1.59 | 0.06 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.06 | -0.01 | -0.01 | 0.00 | Upgrade
|
| Gross Margin | - | - | 69.32% | 50.49% | 65.95% | 91.56% | Upgrade
|
| Operating Margin | - | -57113.60% | -197.58% | -1155.72% | -123.99% | -52.58% | Upgrade
|
| Profit Margin | - | -51161.47% | -197.64% | -1155.50% | -123.95% | -52.58% | Upgrade
|
| Free Cash Flow Margin | - | -38551.27% | -122.21% | -576.27% | -127.42% | 4.32% | Upgrade
|
| EBITDA | -1.08 | -1.8 | -1 | -1.18 | -1.52 | -0.7 | Upgrade
|
| EBITDA Margin | - | - | -166.15% | - | -122.27% | -51.61% | Upgrade
|
| D&A For EBITDA | 0.18 | 0.18 | 0.19 | 0.03 | 0.02 | 0.01 | Upgrade
|
| EBIT | -1.26 | -1.98 | -1.19 | -1.21 | -1.54 | -0.71 | Upgrade
|
| EBIT Margin | - | - | -197.58% | - | -123.99% | -52.58% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.